Hypercoagulopathy in Severe COVID-19: Implications for Acute Care

Link to article at PubMed

Thromb Haemost. 2020 Dec;120(12):1654-1667. doi: 10.1055/s-0040-1721487. Epub 2020 Dec 23.


COVID-19 was first described in late 2019 and has since developed into a pandemic affecting more than 21 million people worldwide. Of particular relevance for acute care is the occurrence of COVID-19-associated coagulopathy (CAC), which is characterised by hypercoagulability, immunothrombosis and venous thromboembolism, and contributes to hypoxia in a significant proportion of patients. This review describes diagnosis and treatment of CAC in the emergency department and in intensive care. We summarise the pathological mechanisms and common complications of CAC such as pulmonary thrombosis and venous thromboembolic events and discuss current strategies for thromboprophylaxis and therapeutic anti-coagulation in the acute care setting.

PMID:33368088 | PMC:PMC7869057 | DOI:10.1055/s-0040-1721487

Leave a Reply

Your email address will not be published.